ALK and cancer: This paper recounts data showing the mechanisms by which two repurposed drugs from general medical practice—itraconazole and cilostazol—intersect with ALK signaling systems and lorlatinib action to potentially augment lorlatinib’s effect or undermine aspects of a cancer’s development of resistance to lorlatinib.